Clinical Trial: Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Brief Summary:
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma.[89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer.A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body.[89Zr]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and…
Read more